<DOC>
	<DOC>NCT00501111</DOC>
	<brief_summary>The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in future trials.</brief_summary>
	<brief_title>Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Provision of informed consent from patient and caregiver Clinical prognosis of probable Alzheimer's disease Patient must have a caregiver visiting the patient at least three times weekly Significant neurologic disease or dementia other than Alzheimer's disease Major depressive disorder, other major psychiatric disorder Use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's disease within 8 weeks prior to enrollment Impaired vision and/or hearing making cognitive testing difficult</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer Type</keyword>
	<keyword>Alzheimer Disease</keyword>
</DOC>